# Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

> **NCT03716024** · PHASE2 · COMPLETED · sponsor: **Paratek Pharmaceuticals Inc** · enrollment: 234 (actual)

## Conditions studied

- Infectious Skin Disease
- Bacterial Skin Disease

## Interventions

- **DRUG:** PTK 0796
- **DRUG:** Linezolid

## Key facts

- **NCT ID:** NCT03716024
- **Lead sponsor:** Paratek Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-18
- **Primary completion:** 2008-01-07
- **Final completion:** 2008-01-07
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2020-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03716024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03716024, "Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03716024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*